CAR-T cell therapy: current limitations and potential strategies

Microenvironmental regulation of tumor progression and metastasis

Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675

Car t cell immunotherapy for human cancer

June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207

Current concepts in the diagnosis and management of cytokine release syndrome.

Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514

Chimeric antigen receptor T-cell therapy—assessment and management of toxicities

Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891

Human gamma-delta (γδ) T cell therapy for glioblastoma: A novel alternative to overcome challenges of adoptive immune cell therapy

Choi, H., Kim, T., Jeun, S., & Ahn, S. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216335 · Cited by 14

Targets of immunotherapy for hepatocellular carcinoma: An update

Rai, V., & Mukherjee, S. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i1.140 · Cited by 14

In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis

Yashaswini, C. N., Cogliati, B., Qin, T., To, T., Williamson, T., Papp, T. E., Li, K., Rasul, R., Chen, L., Lightstone, A., et al. (2025) · doi:10.1101/2025.02.25.640143 · Cited by 13

TSHR in thyroid cancer: bridging biological insights to targeted strategies

Xu, S., Peng, Y., Li, X., Li, H., Liu, T., Li, X., & Du, Y. (2025) · European Thyroid Journal · doi:10.1530/etj-24-0369 · Cited by 13

Chimeric antigen receptor cell therapy: A revolutionary approach transforming cancer treatment to autoimmune disease therapy

Wen, R., Li, B., Wu, F., Mao, J., Azad, T., Wang, Y., Zhu, J., Zhou, X. Y., Xie, H., Qiu, X., et al. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103859 · Cited by 14

LARP4-mediated hypertranslation drives T cell dysfunction in tumors

Liu, Y., Ni, H., Li, J., Yang, J., Sekielyk, I., Snow, B. E., Zhang, Z., Zhang, F., Paul, M. S., Han, J., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02232-5 · Cited by 18

Innate lymphoid cells in the spotlight: from biomarkers to blueprint for innovative immunotherapy

Kuo, I.-C., Brassard, J., Zandstra, P. W., & McNagny, K. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1655730 · Cited by 13

CAR-M therapy in the era of tumor immunotherapy: current research progress and engineering strategies

Yang, Y.-M., Ding, Y.-F., Hu, Y.-Y., Fan, F., & Zhao, J.-L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1723270 · Cited by 14

Engineering autonomous closed-loop designer cells for disease therapy

Mahameed, M., & Fussenegger, M. (2022) · iScience · doi:10.1016/j.isci.2022.103834 · Cited by 13

Advances in the application of Raman spectroscopy in haematological tumours

Liang, H., Shi, R., Wang, H., & Zhou, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1103785 · Cited by 13

Myeloid-derived suppressor cells in head and neck squamous cell carcinoma

He, J.-Y., Huo, F., Tang, H., Liu, B., & Bu, L. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2022.11.002 · Cited by 14

Organoids as an Enabler of Precision Immuno-Oncology

Zhao, J., Fong, A. S. W., Seow, S. V., & Toh, H. C. (2023) · Cells · doi:10.3390/cells12081165 · Cited by 13

DC vaccine enhances CAR-T cell antitumor activity by overcoming T cell exhaustion and promoting T cell infiltration in solid tumors

Zhang, M., Wang, Y., Chen, X., Zhang, F., Chen, J., Zhu, H., Li, J., Chen, Z., Wang, A., Xiao, Y., et al. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03161-1 · Cited by 13

The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer

Akbari, B., Soltantoyeh, T., Shahosseini, Z., Yarandi, F., Hadjati, J., & Mirzaei, H. R. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02948-0 · Cited by 15

CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review

Sadek, N. L., Costa, B. A., Nath, K., & Mailankody, S. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3057 · Cited by 13

Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer

Sayadmanesh, A., Yekehfallah, V., Valizadeh, A., Abedelahi, A., Shafaei, H., Shanehbandi, D., Basiri, M., & Baradaran, B. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111093 · Cited by 16

Site‐Selective Tyrosine Reaction for Antibody‐Cell Conjugation and Targeted Immunotherapy

Chen, H., Wong, H., Qiu, J., Li, B., Yuan, D., Kong, H., Bao, Y., Zhang, Y., Xu, Z., Tse, Y. S., et al. (2023) · Advanced Science · doi:10.1002/advs.202305012 · Cited by 13

Generalized Lerch polynomials: application in fractional model of CAR-T cells for T-cell leukemia

Avazzadeh, Z., Hassani, H., Ebadi, M. J., Zarei‐Behjani, Z., Eshkaftaki, A. B., Mehrabi, S., & Haghighat, S. (2023) · The European Physical Journal Plus · doi:10.1140/epjp/s13360-023-04786-5 · Cited by 13

Advances in synthetic biology-based drug delivery systems for disease treatment

Li, Y., Wang, Y., Luo, Y.-G., Yang, H., Ren, J., & Xiao, L. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.109576 · Cited by 14

Better safe than sorry: dual targeting antibodies for cancer immunotherapy

Schoenfeld, K., Harwardt, J., & Kolmar, H. (2024) · Biological Chemistry · doi:10.1515/hsz-2023-0329 · Cited by 13

Challenges and Opportunities of Gene Therapy in Cancer

Mittal, M., Kumari, A., Paul, B., Varshney, A., Bhavya, B., Saini, A., Verma, C., & Mani, I. (2024) · OBM Genetics · doi:10.21926/obm.genet.2401219 · Cited by 14

Will cellular immunotherapies end neurodegenerative diseases?

Boskovic, P., Gao, W., & Kipnis, J. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.03.006 · Cited by 15

The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases

Shu, J., Xie, W., Chen, Z., Offringa, R., Hu, Y., & Mei, H. (2024) · Med · doi:10.1016/j.medj.2024.03.016 · Cited by 13

Tri-specific killer engager: unleashing multi-synergic power against cancer

Winidmanokul, P., Panya, A., & Okada, S. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00227 · Cited by 13

UniCAR T-Cell Potency—A Matter of Affinity between Adaptor Molecules and Adaptor CAR T-Cells?

Boutier, H., Loureiro, L. R., Hoffmann, L., Arndt, C., Bartsch, T., Feldmann, A., & Bachmann, M. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137242 · Cited by 14

The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity

Nguyen, T., Müller, R., Briukhovetska, D., Weber, J., Feucht, J., Künkele, A., Hudecek, M., & Kobold, S. (2024) · Cancers · doi:10.3390/cancers16142608 · Cited by 13

Current status and future directions of nanovaccine for cancer: a bibliometric analysis during 2004-2023

Hou, Y., Li, Y., Zhang, Y., Zhang, J., & Wu, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1423212 · Cited by 13

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies

Troy, E. C., Caporale, J. R., Sezgin, Y., Pereira, M. D. S. F., Behbehani, G. K., Lyberger, J. M., Lee, D. A., & Kararoudi, M. N. (2024) · Blood Neoplasia · doi:10.1016/j.bneo.2024.100032 · Cited by 13

Improving regulatory T cell-based therapy: insights into post-translational modification regulation

Wang, A., Wang, Y., Liang, R., Li, B., & Pan, F. (2024) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2024.09.014 · Cited by 13

Contemporary strategies in glioblastoma therapy: Recent developments and innovations

Khan, M., Nasim, M., Feizy, M., Parveen, R., Gull, A., Khan, S. M., & Ali, J. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.09.022 · Cited by 13

Ten challenges and opportunities in computational immuno-oncology

Bao, R., Hutson, A. D., Madabhushi, A., Jönsson, V. D., Rosario, S. R., Barnholtz‐Sloan, J. S., Fertig, E. J., Marathe, H. G., Harris, L. N., Altreuter, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009721 · Cited by 14

The guided fire from within: intratumoral administration of mRNA-based vaccines to mobilize memory immunity and direct immune responses against pathogen to target solid tumors

Li, R., Hu, J., Li, R., He, Y., Wang, X., Lin, X., Li, W., Wu, Y., Kuwentrai, C., Su, C., et al. (2025) · Cell Discovery · doi:10.1038/s41421-024-00743-3 · Cited by 13

Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma

Yue, T., Sun, Y., Dai, Y., & Jin, F. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101256 · Cited by 15

Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based Approaches

Fatemi, N., Mirbahari, S. N., Tierling, S., Sanjabi, F., Shahrivari, S., AmeliMojarad, M., AmeliMojarad, M., Rezaei, M. M., Nobaveh, P., Totonchi, M., et al. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08774-2 · Cited by 14

Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases

Huang, Q., Zhu, X., & Zhang, Y. (2025) · Biomarker Research · doi:10.1186/s40364-025-00736-8 · Cited by 15

In vivo armed macrophages curb liver metastasis through tumor-reactive T-cell rejuvenation

Notaro, M., Borghetti, M., Bresesti, C., Giacca, G., Kerzel, T., Mercado, C. M., Beretta, S., Monti, M., Merelli, I., Iaia, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58369-2 · Cited by 13

The next innovations in chimeric antigen receptor T cell immunotherapies for cancer

Anupindi, K., Malachowski, J., Hodson, I., Zhu, D., June, C. H., & Levine, B. L. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.05.010 · Cited by 13

STING agonists: a range of eminent mediators in cancer immunotherapy

Wen, Z., Sun, F., Wang, R., Wang, W., Zhang, H., Yang, F., Wang, M., Wang, Y., & Li, B. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111914 · Cited by 14

Collagen-based biomaterials: recent advances on regulating cell migration and correlated biomedical applications

Zhang, Q., Dou, M., Su, X., Yu, Z., Wei, B., Zhu, L. F., Zhang, J., & Wang, H. (2025) · Collagen and Leather · doi:10.1186/s42825-025-00197-7 · Cited by 17

Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants

Revach, O., Cicerchia, A. M., Shorer, O., Palin, C. A., Petrova, B., Anderson, S., Liu, B., Park, J. C., Chen, L., Mehta, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102210 · Cited by 19

CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies

Marhelava, K., Krawczyk, M., Firczuk, M., & Fidyt, K. (2022) · Cells · doi:10.3390/cells11111804 · Cited by 14

Nanomedicines and cell-based therapies for embryonal tumors of the nervous system

Moukhtari, S. H. E., Garbayo, E., Fernández‐Teijeiro, A., Rodríguez‐Nogales, C., Couvreur, P., & Blanco‐Prieto, M. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.010 · Cited by 14

Advances, challenge and prospects in cell-mediated nanodrug delivery for cancer therapy: a review

Wei, W., Zhang, Y., Lin, Z., Wu, X., Fan, W., & Chen, J. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2104299 · Cited by 13

Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology

Lathuilière, A., Vernet, R., Charrier, E., Urwyler, M., Rohr, O. V., Belkouch, M., Saingier, V., Bouvarel, T., Guillarme, D., Engel, A., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.017 · Cited by 14

A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma

Zhang, G., Zhang, K., Zhao, Y., Yang, Q., & Lv, X. (2022) · BMC Cancer · doi:10.1186/s12885-022-10195-1 · Cited by 13

Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review

Sharma, R., Suravarjhula, L., Banerjee, M., Kumar, G., & Kumar, N. (2023) · Current Drug Research Reviews · doi:10.2174/2589977515666230220092125 · Cited by 13

The Function of Memory CD8+ T Cells in Immunotherapy for Human Diseases

Choi, H., Kim, Y., & Jung, Y. W. (2023) · Immune Network · doi:10.4110/in.2023.23.e10 · Cited by 16

Engineering T Cell Development for the Next Generation of Stem Cell-Derived Immunotherapies

Michaels, Y. S., Durland, L. J., & Zandstra, P. W. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.0008 · Cited by 12

Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies

Chen, E. C., & Garcia, J. S. (2023) · Acta Haematologica · doi:10.1159/000533990 · Cited by 13

Precision Agriculture

Agriculturist, R. N., & Raj, D. K. S. (2023) · doi:10.22192/ttdls.2023.004 · Cited by 13

Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions

Nguyen, D., Liu, R., Ogando‐Rivas, E., Pepe, A., Pedro, D. I., Qdaisat, S., Nguyen, N. T. Y., Lavrador, J. M., Golde, G. R., Smolchek, R. A., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.09.042 · Cited by 17

Cancer‐derived non‐coding RNAs endow tumor microenvironment with immunosuppressive properties

Hu, T., Shi, R., Gu, Y., Zhou, H., Fang, Y., Xu, T., Xu, Y., Wu, X., Ma, L., & Shu, Y. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1822 · Cited by 14

Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma

Bae, J. E., Kitayama, S., Herbert, Z. T., Daheron, L. M., Kurata, K., Keskin, D. B., Livak, K. J., Li, S., Tarannum, M., Romee, R., et al. (2023) · Blood · doi:10.1182/blood.2023020528 · Cited by 13

Deep learning approaches for conformational flexibility and switching properties in protein design

Rudden, L. S. P., Hijazi, M., & Barth, P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.928534 · Cited by 12

Microphysiological systems as models for immunologically ‘cold’ tumors

Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14

Enhancing CAR-T Cell Metabolic Fitness and Memory Phenotype for Improved Efficacy against Hepatocellular Carcinoma

You, J., Yang, X., Zhao, J., Chen, H., Tang, Y., Ouyang, D., Liu, Y., Wang, Y., Xie, S., Chen, Y., et al. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.110406 · Cited by 13

Spleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma model

Wu, Y., Sun, G., Ren, W., Wang, C., Wang, C., Ye, X., Chen, Y., Pang, X., Zhang, Q., Wang, Z. J., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03681-8 · Cited by 15

Heat shock protein 70 (Hsp70) as a target for advancing immunotherapy in solid tumors

Hachani, K., Ghanem, M., Pockley, A. G., Wollenberg, B., Dezfouli, A. B., & Multhoff, G. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.09.002 · Cited by 12

Living drugs: A wonderful evolution for therapeutic applications

Chintalapati, S. S. V. V., Sang, N., Miyahara, M., Iwata, S., Nishida, K., & Miyako, E. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100193 · Cited by 13

Emerging strategies and novel therapeutic targets in acute myeloid leukemia: current advances and future directions

Cao, L., Wang, Z., Cui, Y., Li, Y., & Xiang, Q. (2025) · Biomarker Research · doi:10.1186/s40364-025-00839-2 · Cited by 12

Dendritic cell vaccines: Current research progress, challenges, and opportunities

Zhang, S., Mo, S., Huang, W., Zhong, D., Yang, X., Xie, S., Liu, A., Mo, F., Huang, X., Liu, H., et al. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101913 · Cited by 15

The Current Landscape of Modular CAR T Cells

Joechner, A. H., Mach, M., & Li, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411898 · Cited by 12

Gut microbiota reshaping the pancreatic cancer immune microenvironment: new avenues for immunotherapy

Zheng, S., Li, K.-Z., Feng, G., Wang, Y.-T., Jia-ning, W. A. N. G., Li, S., & Sun, Y.-D. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02513-5 · Cited by 16

Self-transforming hydrogel mimicking tertiary lymph nodes to activate cGAS-STING pathway for enhanced antitumor immunotherapy

Wang, F., Zeng, Y., Yan, M., Zhou, Z., Feng, L., Yang, F., Zhao, W., & Hu, Y. (2026) · Science Advances · doi:10.1126/sciadv.adz5078 · Cited by 12

CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead

Shaer, N. S. H. A., Masoud, I., Tleyjeh, A., Al-Attas, A. A., Al-Attas, M. A., Khan, M. I., & Yaqinuddin, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1796675 · Cited by 15

In vivo CAR-cell therapy: current challenges and emerging therapeutic advances

Yang, Y.-M., Bao, B., Cao, Y.-H., Yao, J., Ding, Y.-F., Hu, Y.-Y., Fan, F., & Zhao, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00447-y · Cited by 13

From bone replacement to regeneration. A biomaterials started journey

Vallet‐Regí, M., Planell, J. A., Lozano, D., & Manzano, M. R. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103282 · Cited by 13

Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies

Wang, H., & Pan, W. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04568-0 · Cited by 12

How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care

Cipri, S., Abenavoli, L., Boccuto, L., Baldo, G. D., & Mastronuzzi, A. (2022) · Medicina · doi:10.3390/medicina58101386 · Cited by 13

The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy

Arman, I., Haus‐Cohen, M., & Reiter, Y. (2022) · Cells · doi:10.3390/cells12010027 · Cited by 11

The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer

Meng, S., Li, M., Qin, L., Lv, J., Wu, D., Zheng, D., Jia, H., Chen, D., Wu, Q., Long, Y., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110402 · Cited by 12

Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma

Chatwal, M. S., Chahoud, J., & Spiess, P. E. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.09 · Cited by 12

Cbl induced ubiquitination of HER2 mediate immune escape from HER2‐targeted CAR‐T

Yang, Y., Sun, Q., Deng, Z., Shi, W., & Cheng, H. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23446 · Cited by 12

4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T

Shen, X., Zhang, R., Nie, X., Yang, Y., Hua, Y., & Lü, P. (2023) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2023.0022 · Cited by 13

FEN1 inhibitor SC13 promotes CAR‐T cells infiltration into solid tumours through cGAS–STING signalling pathway

Dong, Y., Wang, Y., Yin, X., Zhu, H., Liu, L., Zhang, M., Chen, J., Wang, A., Huang, T., Hu, J., et al. (2023) · Immunology · doi:10.1111/imm.13681 · Cited by 12

Gene-activating nanomedicine for the tumor-oriented infiltration of T cells to enhance immunotherapy against solid tumors

Zhang, Y., Zhao, G., Liu, J., Zhang, H., Wang, Y., Luo, Y., Lu, Z.-D., Lu, Z.-D., Shen, S., Du, J., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101992 · Cited by 12

Systems immunology spanning tumors, lymph nodes, and periphery

Sidiropoulos, D. N., Ho, W. J., Jaffee, E. M., Kagohara, L. T., & Fertig, E. J. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100670 · Cited by 12

Photothermal Prussian blue nanoparticles generate potent multi‐targeted tumor‐specific T cells as an adoptive cell therapy

Sweeney, E. E., Sekhri, P., Muniraj, N., Chen, J., Feng, S., Terao, J., Chin, S. J., Schmidt, D. E., Bollard, C. M., Cruz, C. C., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10639 · Cited by 12

NK cells as powerful therapeutic tool in cancer immunotherapy

Huang, M., Liu, Y., Yan, Q., Miao, P., Ge, J., Mo, Y., Wang, Y., Wang, F., Zeng, Z., Li, Y., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-023-00909-3 · Cited by 12

Therapeutic approaches of cell therapy based on stem cells and terminally differentiated cells: Potential and effectiveness

Pirsadeghi, A., Namakkoobi, N., Behzadi, M. S., Pourzinolabedin, H., Askari, F., Shahabinejad, E., Ghorbani, S., Asadi, F., Hosseini‐Chegeni, A., Yousefi‐Ahmadipour, A., et al. (2024) · Cells and Development · doi:10.1016/j.cdev.2024.203904 · Cited by 17

Nano-chemical priming strategy to enhance TGF-β resistance and anti-tumor activity of natural killer cells

Choi, S. H., Cho, H. B., Choi, J., Kim, H. J., Jang, H. J., Cho, S., Maeng, E., Park, H., Ryu, K. S., Park, K., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.008 · Cited by 12

Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)

Yu, T., Jiang, W., Wang, Y., Zhou, Y. Y., Jiao, J., & Wu, M. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5628 · Cited by 12

Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme: Literature review and future directions

Goutnik, M., Iakovidis, A., Still, M. E., Moor, R. S. F., Melnick, K. F., Yan, S. C., Abbas, M., Huang, J., & Ghiaseddin, A. P. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae025 · Cited by 12

Non-viral delivery of RNA for therapeutic T cell engineering

Berdecka, D., Smedt, S. C. D., Vos, W. H. D., & Braeckmans, K. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115215 · Cited by 14

Tumour‐associated neutrophils: Potential therapeutic targets in pancreatic cancer immunotherapy

Wu, Q., Mao, H., Jiang, Z., & Tang, D. (2024) · Immunology · doi:10.1111/imm.13765 · Cited by 12

High-multiplex single-cell imaging analysis reveals tumor immune contexture associated with clinical outcomes after CAR T cell therapy

Jin, J., Li, L., Meng, J., Jiang, L., Zhang, M., Fang, Y., Liu, W., Xin, X., Long, X., Kuang, D., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.023 · Cited by 12

The heterogeneity of tumour-associated macrophages contributes to the clinical outcomes and indications for immune checkpoint blockade in colorectal cancer patients

Tang, J., Liang, M., Qin, F., Qin, Y., Wang, D., Huang, L., Cao, Y., Huang, Z., & Yin, Y. (2024) · Immunobiology · doi:10.1016/j.imbio.2024.152805 · Cited by 12

Change in Neurocognitive Function in Patients Who Receive CAR-T Cell Therapies: A Steep Hill to Climb

Strongyli, E., Evangelidis, P., Sakellari, I., Gavriilaki, M., & Gavriilaki, E. (2024) · Pharmaceuticals · doi:10.3390/ph17050591 · Cited by 13

Biomaterial‐Based Therapeutic Delivery of Immune Cells

Dravid, A. A., Singh, A. K., & Garcı́a, A. J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400586 · Cited by 12

Development of novel humanized CD19 / BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B‐cell lineage neoplasms

Wu, S., Luo, Q., Li, F., Zhang, S., Zhang, C., Liu, J., Shao, B., Yang, H., Tan, T., Dong, X., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19631 · Cited by 13

Tumor microenvironment: A playground for cells from multiple diverse origins

Bharadwaj, D., & Mandal, M. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189158 · Cited by 13

Comprehensive macro and micro views on immune cells in ischemic heart disease

Zhao, Y., Tan, M., Yin, Y., Zhang, J., Song, Y., Li, H., Lin, Y., Jin, Y., Wu, Z., Yang, T., et al. (2024) · Cell Proliferation · doi:10.1111/cpr.13725 · Cited by 13

Acute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope

Jing, J., Ma, Y., Xie, Z., Wang, B., Chen, Y., Chi, E., Wang, J., Zhang, K., Wang, Z., & Li, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410519 · Cited by 13

Leukemia Cell Hitchhiking Hypoxia Responsive Nanogel for Improved Immunotherapy of Acute Myeloid Leukemia

Chen, H., Wang, D., Yao, Y., Xiao, Y., Zhao, Z., Zhang, Z., Liu, S., Wang, X., Yang, S., Huang, P., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202411439 · Cited by 12

Chimeric antigen receptor T-cell therapy in patients with malignant glioma—From neuroimmunology to clinical trial design considerations

Gallus, M., Young, J. S., Quackenbush, S. C., Khasraw, M., de Groot, J., & Okada, H. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae203 · Cited by 14

GD2 in Breast Cancer: A Potential Biomarker and Therapeutic Target

Mokbel, K. (2024) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20471 · Cited by 12

Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer

Torchiaro, E., Cortese, M., Petti, C., Basiricò, M., Invrea, F., D'Andrea, A., Franco, L., Sangiolo, D., & Médico, E. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05851-y · Cited by 12

Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis

Koh, S. K., Kim, H., Han, B., Jo, H., Doh, J., Park, J., Nguyen, M. H., Kim, H., Kim, H., Lee, S., et al. (2024) · Blood · doi:10.1182/blood.2024025673 · Cited by 12

CAR T Cell Nanosymbionts: Revealing the Boundless Potential of a New Dyad

Baena, J. C., Pérez, L. M., Toro-Pedroza, A., Kitawaki, T., & Loukanov, A. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313157 · Cited by 13

Efficacy and safety of anti-CD19 CAR-T in a mouse model of IgG4-related disease

Sun, Y., Huang, S., Zhang, B., Peng, Y., Lu, H., Jia, Y., Sun, R., Zhang, F., 周佳鑫, Peng, L., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113779 · Cited by 12

CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer

Mavi, A. K., Gaur, S., Gaur, G., Babita, B., Jindal, P., Kumar, N., & Kumar, U. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110638 · Cited by 24

CAR T‐Cell‐Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Jogalekar, M. P., Rajendran, R. L., Khan, F., Dmello, C., Gangadaran, P., & Ahn, B.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925985 · Cited by 214

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

Sorkhabi, A. D., Khosroshahi, L. M., Sarkesh, A., Mardi, A., Aghebati‐Maleki, A., Maleki, L. A., & Baradaran, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113882 · Cited by 219

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,525

CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies

Huang, J., Huang, X., & Huang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019115 · Cited by 72